Trial · NCT07895225
PRP Versus NP Injections for Chronic Discogenic Low Back Pain
NCT07895225, Phase 2, Phase 3, Not yet recruiting, Walter Reed National Military Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRP Versus NP Injections for Chronic Discogenic Low Back Pain. Trials, record NCT07895225. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895225
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRP Versus NP Injections for Chronic Discogenic Low Back Pain
- NCT number
- NCT07895225
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Walter Reed National Military Medical Center
- Conditions
- Discogenic Low Back Pain
- Interventions
- Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection
- First posted
- 2026-10-26
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Between-Group Difference in Mean Change in Average LBP (NPRS) | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. Change from Baseline to 6 months is the primary outcome. | The 11-item NPRS scale is a unidimensional measure of pain intensity. It is a segmented numeric version of the visual analog scale in which participants will select a whole number (0-10 integers) that best reflects the intensity of their pain. The scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. worst possible pain). |
| Secondary | Between-Group Difference in Mean Change in Function (ODI) | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. 6 months is the primary timepoint. | The Oswestry Disability Index (ODI) is a 10-item questionnaire that measures the impact of low back pain on an individual's overall function. The ODI is scored on a scale from 0-100%, where a lower percentage reflects better function. |
| Secondary | Patient Perception of Change/Satisfaction | Will capture at 1-, 3-, 6-, and 12-months from Baseline. 6 months is the primary timepoint. | The Patient Global Impression of Change (PGIC) is a 7-point Likert scale to measure changes in overall clinical status and satisfaction in response to an intervention. The PGIC has the following response options: 1 - No change (or condition has gotten worse); 2 - Almost the same, hardly any change at all; 3 - A little better, but no noticeable change; 4 - Somewhat better, but the change has not made any real difference; 5 - Moderately better, and a slight but noticeable change; 6 - Better and a definite improvement that has made a real and worthwhile difference; 7 - A great deal better and a considerable improvement that has made all the difference. |
| Secondary | Proportion of Participants with Significant Medication Reduction | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. 6 months is the primary timepoint. | Medication use will be assessed at each timepoint. A reduction \> 20% in opioid usage or cessation of a non-opioid analgesic will be considered significant. The proportion of participants with a significant medication reduction will be reported. |
| Secondary | Proportion of Participants with Positive Categorical Outcome | Will capture at 1-, 3-, 6-, and 12-months from Baseline. 6 months is the primary timepoint. | A positive categorical outcome is defined as a ≥ 2-point decrease in average NPRS score coupled with a PGIC score ≥ 5/7 or ≥ 10-point decrease in ODI, without significant supplemental medication use. |
| Secondary | Effect on Quality of Life (HADS) | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. 6 months is primary timepoint. | The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire scored from 0-21, where low scores indicate lower levels of anxiety and depression. The HADS provides additional information on an individual's overall quality of life in terms of mental health. |
| Secondary | Effect on Quality of Life (AIS) | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. 6 months is primary timepoint. | The Athens Insomnia Scale (AIS) is an 8-item questionnaire scored from 0-24, where low scores indicate lower levels of insomnia. The AIS provides additional information on an individual's overall quality of life in terms of sleep quality. |
| Secondary | Between-Group Difference in Average LBP (DVPRS) | Change from Baseline to 1-, 3-, 6-, and 12-months will be assessed. 6 months is the primary timepoint. | The Defense Veterans Pain Rating Scale (DVPRS) is a 11-point scale measuring pain intensity, where a lower score indicates less pain. 4 additional supplemental questions are included if average pain level is ≥ 4/10. |
| Secondary | Demographic and Clinical Predictors of Treatment Response | Will capture at Baseline, 1-, 3-, 6-, and 12-months. 6 months is the primary timepoint. | Subgroup exploratory analyses will be performed to determine whether any demographic and clinical variables (e.g., biological sex, baseline pain severity, cell and immunoregulatory profiles) predict treatment response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895225
GET https://conductscience.org/api/trials/v1/NCT07895225/registered